Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000912282-17-000092
Filing Date
2017-04-14
Accepted
2017-04-14 13:29:18
Documents
7
Period of Report
2017-04-12

Document Format Files

Seq Description Document Type Size
1 oncolytics6k_041217.htm 6-K 19267
2 NOTICE OF ANNUAL GENERAL MEETING AND MANAGEMENT INFORMATION CIRCULAR DATED MARCH ex99_1.htm EX-99.1 769845
3 image0.jpg GRAPHIC 69728
4 image1.jpg GRAPHIC 68531
5 image2.jpg GRAPHIC 66946
6 image3.jpg GRAPHIC 38663
7 image00004.jpg GRAPHIC 20765
  Complete submission text file 0000912282-17-000092.txt   1154864
Mailing Address 210 - 1167 KENSINGTON CRES NW CALGARY A0 T2N 1X7
Business Address 1167 KENSINGTON CRES NW SUITE 210 CALGARY ALBERTA CANADA T2N 1X7 ALBERTA CANADA A0 00000 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 000-31062 | Film No.: 17762607
SIC: 2834 Pharmaceutical Preparations